Alle afleveringen
282 afleveringen, van nieuw naar oud
-
Episode 256 - Sean Ekins - Collaborations Pharmaceuticals
4 november 2026 · 30 min
In this episode of The BioHub, Amber is joined by Dr. Sean Ekins, Founder and CEO of Collaborations Pharmaceuticals. Lees meer
Sean shares his perspective on the evolving role of machine learning in drug discovery, how computational approaches can support rare and neglected disease research, and what it really takes to move from prediction to meaningful therapeutic development.
They also discuss the opportunities and limitations of AI in chemistry, the importance of scientific collaboration, and some of the wider questions around responsible innovation and dual-use risk as generative drug discovery continues to develop.
-
Episode 255 - Jason Goodson - COO at PleoPharma
2 november 2026 · 20 min
n this episode of The BioHub, we welcome Jason Goodson, Chief Operating Officer at PleoPharma, a clinical-stage biotechnology company developing innovative treatments for cannabis use disorder and cannabis withdrawal syndrome. Lees meer
With millions of Americans affected by cannabis use disorder and no FDA-approved medications specifically targeting cannabis withdrawal, PleoPharma is working to address a significant unmet need through its lead candidate, PP-01, now in pivotal Phase 3 development.
Jason shares insights into the growing market for addiction therapeutics, the clinical and commercial potential of PP-01, and the challenges of bringing a first-in-class treatment to market.
We also explore the strategic decisions behind scaling a clinical-stage biotech, from financing and partnerships to commercial readiness, leadership, and building the right team for future growth.
-
Episode 254 - Erick Lucera (CFO) & Vikram Ranade (CBO) at Dyne Therapeutics
29 oktober 2026 · 29 min
Today, we’re joined by Erick Lucera, Chief Financial Officer, and Vikram Ranade, Chief Business Officer at Dyne Therapeutics. We’ll be discussing their individual journeys through biotech, what attracted them to Dyne, and the company’s mission to develop transformative treatments for people living with genetically driven neuromuscular diseases. We’ll also explore the strategy behind building a biotech towards commercialisation, the financial and business development challenges involved, and their perspectives on the wider biotech landscape. Lees meer
-
Episode 253 - John Yu CEO at Kairos Pharma
26 oktober 2026 · 16 min
In this episode of The BioHub Podcast, Ben is joined by Dr. John Yu, CEO and Chairman of Kairos Pharma, a clinical-stage biotechnology company developing innovative therapies to overcome drug resistance and immune suppression in cancer. Lees meer
Dr. Yu brings a unique perspective from his extensive career in neurosurgery, oncology, immunology, and biotechnology entrepreneurship. Together, they explore his journey from academic medicine into biotech leadership, the science behind Kairos Pharma's approach to tackling cancer drug resistance, and the development of its lead candidate, ENV105, which targets CD105 to potentially restore sensitivity to existing cancer treatments.
The conversation also examines the challenges of translating academic discoveries into clinical therapies, building and financing an emerging biotechnology company, and the opportunities ahead for improving cancer treatment outcomes.
An insightful discussion on scientific innovation, entrepreneurship, and the journey from breakthrough research to meaningful patient impact.
-
Episode 252 - Sam Reich - CEO at SAB Bio
26 oktober 2026 · 25 min
In this episode of The BioHub by Avetix, I’m joined by Sam Reich, CEO of SAB BIO. Lees meer
Sam shares his unconventional journey from leaving his PhD to build his first biotech, through founding and selling companies, working with influential industry figures like Phil Frost, and eventually leading Big Cypress Acquisition Corp.
We discuss how that journey brought him to SAB BIO, why the company became the right opportunity, the challenges behind its strategic pivot towards type 1 diabetes, and what it takes to keep adapting when the path of a biotech changes.
We also explore the lessons Sam has learned from building, financing and leading companies across multiple stages, and what comes next for SAB as it works to develop a disease-modifying treatment for type 1 diabetes.
-
Episode 250 - Dr. Garry Pairaudeau, Co-Founder CEO & Dr. Anthony Bradley, Co-Founder CSO of Dalton Tx
22 oktober 2026 · 30 min
In this episode of The BioHub, Amber is joined by Dr. Garry Pairaudeau, Co-Founder and CEO, and Dr. Anthony Bradley, Co-Founder and CSO of Dalton Tx. Lees meer
Having previously worked together at Exscientia, Garry and Anthony went on to co-found Dalton Tx. bringing together AI, scientific expertise and software engineering to help accelerate drug discovery.
We explore their journey the challenges of translating advances in AI into meaningful scientific impact, and the importance of separating genuine innovation from industry hype.
We also discuss the evolving role of AI in drug discovery, building a science-driven company, and what the future could hold for AI-enabled therapeutics.
-
Why Biotech Keeps Reinventing the Wheel | Greg Crescenzi, Addgene
21 oktober 2026 · 18 min
Why spend months recreating research tools that another lab has already built? Lees meer
In this episode of The BioHub, we’re joined by Greg Crescenzi from Addgene to discuss how sharing scientific materials can reduce duplicated work, save researchers time and help biotech discoveries move faster.
From plasmids and CRISPR tools to viral vectors and antibodies, Greg explains how Addgene helps scientists build on existing research—and why improving access between academia and industry is the next challenge.
We cover:
• The frustration that sparked Addgene’s founding
• How sharing research tools helped CRISPR reach thousands of organisations
• The barriers between academic research and commercial biotech
• Partnerships supporting better sequencing and new research tools
• Why unsuccessful experiments contain information worth sharing
• Where AI and Addgene’s research data could create new opportunitiesSubscribe to The BioHub for more conversations with the people advancing biotech.
#Biotech #Addgene #CRISPR #BioHub
-
Episode 248- Marshall Fordyce - Founder & CEO of Vera Therapeutics
20 oktober 2026 · 27 min
In this episode of The BioHub by Avetix, I’m joined by Marshall Fordyce, Founder and CEO of Vera Therapeutics. Lees meer
Marshall shares his journey from medicine and HIV drug development at Gilead to founding Vera, and how that experience shaped his belief in the power of building medicines that can genuinely change the course of disease.
We discuss what patient-centricity looks like in practice, the thinking behind Vera’s Phase III strategy, and the company’s transition from development-stage biotech into commercial launch. Marshall also shares his framework for building biotech companies, why people and capital discipline matter just as much as the science, and what comes next for Vera as it continues the US launch of Trutacna.
-
Episode 247 - Chris Moxham Founder & CEO and Clayton Mellina CTO of Transcripta Bio
19 oktober 2026 · 25 min
In this episode of The BioHub, Amber is joined by Dr. Chris Moxham, Co-founder and CEO of Transcripta Bio, and Clayton Mellina, CTO, to explore how transcriptomics and AI are opening up new possibilities in drug discovery. Lees meer
Chris and Clayton explain how Transcripta connects the changes disease causes in cells with the effects of potential treatments. They discuss combining phenotypic screening with target-based discovery, finding new uses for existing medicines, and reducing risk earlier in development.
The conversation covers their work in genetically defined autism spectrum disorders and Huntington’s disease, their collaboration with Mayo Clinic, and how AI agents could help small scientific teams explore thousands of hypotheses.
-
Episode 246 - Neil Warma - CEO, ProMIS Neurosciences
19 oktober 2026 · 39 min
In this episode of The BioHub Podcast by Avetix, we welcome Neil Warma, President and CEO of ProMIS Neurosciences, a clinical-stage biotechnology company developing next-generation therapies targeting toxic, misfolded proteins associated with neurodegenerative diseases. Lees meer
Neil shares insights from his extensive career building and leading biotechnology companies, before exploring ProMIS' differentiated approach to treating Alzheimer's disease. We discuss PMN310, an antibody designed to selectively target toxic amyloid-beta oligomers while avoiding plaque, its ongoing Phase 1b PRECISE-AD clinical trial, and the potential to improve both efficacy and safety in Alzheimer's treatment.
The conversation also explores ProMIS' broader ambitions across ALS and Parkinson's disease, upcoming clinical milestones, and Neil's perspective on leadership, financing, and building successful biotechnology companies.
-
Episode 245 - Michael Fenn CBO Bexorg
14 oktober 2026 · 41 min
On this episode of The BioHub, Amber Hayes is joined by Michael Fenn, Chief Business Officer at Bexorg, a precision neurology company combining AI with a pioneering whole-human brain platform to transform CNS drug discovery. Lees meer
Michael brings experience spanning biotech investing, business development and company building, including previous roles at Dewpoint Therapeutics and Iaso Ventures. He shares his journey across the industry, what attracted him to Bexorg, and why he believes the company’s approach could fundamentally change how neurological therapies are discovered and developed.
We discuss the challenges of translating neuroscience research into effective treatments, how Bexorg is combining human brain pharmacology with AI to bridge the gap between preclinical research and clinical success, and the opportunities and challenges of building a platform-driven biotech.
-
Episode 244 - Erik Wiklund & Thomas Hansen - CEO & CTO of Circio
12 oktober 2026 · 30 min
On this episode, we sit down with the CEO & CTO of Circio to get into the world of circular RNA. Lees meer
Erik, Thomas and the team are developing circVec, a circular RNA expression platform designed to make C&G therapies more powerful and durable.
The guys dig into the science & history behind circular RNA before discussing some initial data they have in heart, brain and other tissues, whilst explaining why this matters.
We also touch on the platform vs internal pipeline debate, their recent fundraising, partnering discussions and what to expect from Circio in the next 18 months.
-
Episode 243 - Johanna Kaufman: CSO at DeckBio
8 oktober 2026 · 28 min
We were delighted to be joined by Johanna Kaufmann, Chief Scientific Officer at Deck Bio. Lees meer
Johanna has spent her career at the intersection of oncology, immunology and drug development, working across both biotech and big pharma. She started her career in cancer virology before moving through roles at Genocea, TESARO and GSK, and later joined Codagenix, where she led its oncology and immunology efforts.
Today, as CSO at Deck Bio, she’s helping to advance a new approach to targeting solid tumours through multi-peptide-MHC targeted T-cell engagers.
In this we discuss Johanna’s journey through the field, the lessons she’s learned moving between different parts of the industry, how her thinking around drug development has evolved, and what it takes to build and advance innovative science in biotech.
-
Episode 242 - Sam Blackman
7 oktober 2026 · 52 min
We were delighted to be joined by Dr. Sam Blackman, a physician-scientist, biotech entrepreneur and investor who has built a fascinating career across medicine, drug development and biotechnology. Lees meer
Sam trained as a physician and spent much of his early career focused on pediatric oncology before moving into the biotech world, where he became one of the co-founders of Day One Biopharmaceuticals. He played a key role in building the company and advancing tovorafenib through development and ultimately to FDA approval for children and young adults with relapsed or refractory low-grade glioma.
Since then, Sam has moved into a broader role across the biotech ecosystem, including working with companies as an investor, advisor and board member.
-
Episode 241 - Howard Berman & Kia Motesharei - ReAlta Life Sciences
6 oktober 2026 · 34 min
We were delighted to be joined by two highly experienced leaders in the biotechnology industry, Howard Berman, Ph.D., and Kia Motesharei, Ph.D. Lees meer
Both Howard and Kia have built impressive careers across biotechnology, capital markets, business development and strategic transactions, with a track record of helping companies navigate some of the most important stages of their growth.
Howard is now CEO of ReAlta Life Sciences, where he is leading the company through an important clinical-stage period as it advances pegtarazimod into late-stage development. Kia serves as President and COO, bringing extensive experience across business development, strategic partnerships, capital formation and transactions. Together, they bring a particularly interesting perspective on how to create value in biotech and how the right strategy, leadership and capital can come together to move a company forward.
-
Episode 240 - Inder Kaul - CMO at Draig Therapeutics
5 oktober 2026 · 27 min
In this episode of The BioHub Podcast, Ben sits down with Dr. Inder Kaul, Chief Medical Officer at Draig Therapeutics, to discuss the evolution of neuropsychiatric drug development and what it takes to translate novel neuroscience into meaningful medicines for patients. Lees meer
Inder brings decades of global clinical development experience, most recently playing a key role in the development of Cobenfy at Karuna Therapeutics and Bristol Myers Squibb - one of the most significant advances in schizophrenia treatment in decades.
We explore the journey behind Cobenfy, what its success tells us about pursuing new mechanisms in psychiatry, and the lessons Inder has taken into his current role at Draig.
The conversation also dives into Draig’s approach to neuropsychiatry, including its Phase 2 AMPA receptor modulator DT-101 for major depressive disorder, the potential of targeting glutamate and GABA pathways, and what the next generation of CNS drug development could look like.
A fascinating conversation with someone who has helped take genuinely differentiated neuroscience from clinical development through to approval.
-
Episode 239 - Eran Seger - CEO & Co-Founder Protai
5 oktober 2026 · 24 min
In this episode of The BioHub by Avetix, I’m joined by Eran Seger, CEO and Co-Founder of Protai. Lees meer
Eran shares his unique journey into biotech and the inspiration behind founding Protai, where the team is combining proteomics and AI to better understand disease biology and improve how new medicines are discovered.
We discuss what makes Protai’s platform different, the realities of being a first-time founder and CEO, the challenge of bringing technology and biotech teams together, and where Eran believes AI can genuinely transform drug discovery.
-
Episode 238 - Mandana Honu Fathom Therapeutics
1 oktober 2026 · 27 min
We welcomed Mandana Honu onto the BioHub podcast
-
Episode 237 - Marc Hedrick & Russell Bradley- Cerenome
1 oktober 2026 · 31 min
In this episode of The BioHub Podcast, Ben is joined by Dr. Marc Hedrick, President & CEO of Cerenome, and Russell Bradley, President & General Manager of CNSide Diagnostics. Lees meer
We explore why CNS cancers remain so difficult to diagnose and treat, and how Cerenome is attempting to address both sides of that problem.
Russell takes us inside CNSide®, the company’s cerebrospinal fluid-based diagnostic platform, including how it differs from traditional cytology, the importance of rare-cell characterisation, and what better diagnostic information could mean for treatment decisions.
Marc then discusses REYOBIQ™, Cerenome’s targeted radiotherapeutic platform, the challenge of delivering sufficient therapeutic intensity into the CNS while managing toxicity, and the broader opportunity to connect diagnosis, treatment and longitudinal monitoring.
A fascinating conversation at the intersection of diagnostics, therapeutics and precision CNS oncology.
-
Episode 236 - Dan O’Connell - President & CEO of Acumen Pharmaceuticals
30 september 2026 · 27 min
In this episode of The BioHub by Avetix, I’m joined by Dan O’Connell, President and CEO of Acumen Pharmaceuticals. Lees meer
Dan shares his journey from neuroscience investing and company creation into the CEO role, and how he has helped take Acumen from a private, preclinical biotech into a publicly traded clinical-stage company focused on Alzheimer’s disease.
We discuss the origins of Acumen, what it was like taking the company public with just nine people, navigating a difficult few years for biotech, balancing financial discipline with clinical progress, and the major readout ahead later this year.
-
Episode 235 - Paul Hastings - CEO NKarta
25 september 2026 · 42 min
In this episode of The BioHub by Avetix, I’m joined by Paul Hastings, CEO of Nkarta. Lees meer
Paul has spent more than three decades in biotech, leading companies across oncology, rare disease and cell therapy, while also becoming one of the industry’s most prominent patient advocates. At Nkarta, he’s now leading the development of allogeneic NK cell therapies designed to make cell therapy safer, more scalable and more accessible.
We discuss the evolution of biotech since Paul entered the industry in 1989, the future of cell therapy, the challenges of scaling access, the US clinical and regulatory environment, the importance of patient advocacy, and the mentors and lessons that have shaped his career.
-
Epsiode 234 - Lei Fang CEO Excalipoint
25 september 2026 · 25 min
We welcomed Lei Fang the CEO of Excalipoint to the BioHub
-
Episode 233 - Jay Fine - President R&D at Evolveimmune Therapeutics
24 september 2026 · 36 min
Today we’re joined by Jay Fine, President of Research & Development at EvolveImmune Therapeutics. Lees meer
Jay has spent more than 30 years working across drug discovery and development, with a career spanning immunology, immuno-oncology, inflammatory diseases and respiratory disorders. Before joining EvolveImmune, he spent many years at Boehringer Ingelheim, where he led global research efforts in immunology and respiratory diseases, with his teams playing a key role in advancing therapies including Skyrizi and Spevigo.
Earlier in his career, Jay held leadership and research positions at Roche, Schering-Plough and the National Cancer Institute, giving him experience across academia, large pharma and biotech.
Today, we’ll talk about Jay’s journey through the field, the lessons he’s learned from taking medicines from discovery into development, his experience building and leading scientific teams, and what he sees as the biggest opportunities and challenges in drug development today.
-
Episode 232 - Alan Bash - President Legend Biotech
24 september 2026 · 23 min
Editor’s note: At the time of recording, Alan Bash was serving as Interim CEO of Legend Biotech. He has since resumed his role as President of CARVYKTI® following the appointment of Ingrid Zhang as CEO. Lees meer
In this episode of The BioHub by Avetix, I’m joined by Alan Bash, President of CARVYKTI® at Legend Biotech.
Alan shares what drew him to Legend, what he believes has made the company such a standout success in cell therapy, and his experience stepping into the Interim CEO role during an important period of transition.
We also discuss the journey behind CARVYKTI, the importance of global partnerships, the challenges of manufacturing and scaling cell therapy, and what the next chapter could look like for Legend as it builds beyond its first major commercial success.
-
Episode 231 - Stacy Blain - CEO & Founder of Concarlo Therapeutics
22 september 2026 · 39 min
Today we’re joined by Dr. Stacy Blain, Founder and CEO of Concarlo Therapeutics. Lees meer
Stacy has spent more than 30 years working in cell cycle and cancer biology, including two decades as a tenured professor and NIH-funded researcher at SUNY Downstate. She then made the transition from academia into entrepreneurship, founding Concarlo to develop new approaches to treating drug-resistant cancers.
At Concarlo, Stacy and the team are focused on p27 biology and developing their LOCKTAC approach to target CDK2, CDK4 and CDK6, with an initial focus on drug-resistant breast cancer.
Today, we’ll talk about Stacy’s journey from academic scientist to biotech founder, what led her to make that transition, the science behind Concarlo, and what she’s learned from building a company around her own research.
-
Episode 230 - Nick Sireau - Chairman at Serenatis Bio
21 september 2026 · 24 min
In this episode of The BioHub Podcast by Avetix, Ben O’Keefe sits down with Nick Sireau, Executive Chairman and Co-Founder of Serenatis Bio, to discuss the company’s mission to develop a new generation of treatments for obsessive-compulsive disorder (OCD). Lees meer
Nick shares the deeply personal story behind Serenatis, from his own experience living with OCD to the loss of a close friend to the condition, and how that ultimately helped shape the company’s focus.
They explore why OCD remains a significantly underserved area of neuropsychiatry, what the biology of compulsivity can teach us more broadly, and Serenatis’ approach to developing novel mechanisms targeting glutamate, neuroinflammation and dopamine-related pathways.
Nick also discusses the company’s lead programme, plans to enter Phase 1b development, the role neuroimaging could play in demonstrating early proof of biology, and what Serenatis is aiming to achieve over the next 18 months.
A fascinating conversation on building a neuroscience company around both strong biology and a very personal mission.
-
Episode 229 - Frederic Marrache - CEO of Bionyra
21 september 2026 · 27 min
On this episode we feature the CEO of Bionyra, Frederic Marrache, after closing French-biotech's largest ever Series A ($165million) this summer. Lees meer
Bionyra are a Sofinnova-incubated I&I biotech advancing in-licensed monoclonal (TL1A & IL25) & bispecific (TL1AxIL-23p19) HLE antibodies for a range of autoimmune indications. In this conversation we discuss why, after a decade within Sanofi's I&I development organisation, Frederic viewed the Bionyra opportunity as 'the one' to scratch his biotech itch.
Naturally, we then discuss the promise of their technology which led to the likes of Jeito & Sanofi's CVC to participate in their record breaking Series A. Frederic also discusses indication expansion possibilities, and an upcoming 18-24 months that promise to be milestone-rich.
One to check-out for anyone interested in immunology drug-development and particularly those with an eye on company building in Europe.
-
Episode 228 - Edward Van Wezel - Founder BGV
17 september 2026 · 29 min
In this episode of The BioHub by Avetix, I’m joined by Edward van Wezel, Managing Partner and Co-Founder of BioGeneration Ventures. Lees meer
Edward shares his journey into venture capital and the story behind building BGV into one of Europe’s leading early-stage life sciences investors. We discuss how he evaluates companies at the earliest stages, what he looks for in founders and leadership teams, and the lessons behind standout investments such as Acerta Pharma.
We also explore the evolution of the European biotech ecosystem, the challenges of fundraising and company creation, and what Edward believes Europe needs to do to build more globally competitive biotech companies.
-
Episode 227 - Jo Lane - VP People at Compass Pathways
15 september 2026 · 33 min
Today, I’m joined by Jo Lane, a senior People and HR leader currently working with COMPASS Pathways, where she plays a key role in supporting the organisation and its people as the company continues to develop and grow. Lees meer
Jo has built an impressive career across the life sciences and healthcare sectors, with senior HR and organisational development roles at COMPASS Pathways, Ipsen and IQVIA. Her experience spans people strategy, organisational development, talent, leadership, change and building high-performing teams across global organisations.
Today, we’re going to talk about Jo’s journey through HR and into biotech, her experience supporting companies through periods of growth and transformation, and what she’s learned about building the right culture and teams along the way. We’ll also explore leadership, talent retention and how the role of HR continues to evolve within the biotech industry.
-
Episode 226 - Tony Estrada - CEO & Co-founder Tenvie Therapeutics
15 september 2026 · 24 min
In this episode of The BioHub by Avetix, I’m joined by Tony Estrada, Co-Founder and CEO of Tenvie Therapeutics. Lees meer
Tony shares his journey from Genentech and Denali Therapeutics to founding Tenvie, and why he chose to build a company focused on some of the toughest challenges in neuroscience. We discuss what it takes to launch a biotech in a difficult funding environment, why being scrappy and disciplined matters, and how Tenvie is balancing near-term clinical progress with continued investment in discovery.
We also explore the future of neuroscience, the importance of mentorship, and where Tony believes AI and machine learning can genuinely improve drug discovery.
-
Episode 225 - Kristen Stants - Chief People Officer Parabalis
14 september 2026 · 22 min
In this episode of The BioHub by Avetix, I’m joined by Kristen Stants, Chief People Officer at Parabilis Medicines. Lees meer
Recorded shortly after Parabilis completed its record-breaking IPO, Kristen shares what that milestone means for the company and how the people strategy changes when a biotech suddenly enters a new phase of rapid growth.
We also discuss how to protect culture while scaling, the qualities that help people thrive in biotech, what strong leadership looks like in a volatile industry, and Kristen’s advice for the next generation looking to build a career in HR.
-
Episode 224 - Wyatt McDonnell - CEO of Infinimmune
11 september 2026 · 36 min
On this episode of the podcast we feature CEO & Co-Founder of Infinimmune, Wyatt McDonnell, to discuss a hugely impressive & milestone-rich journey since founding in 2022. Lees meer
Infinimmune was founded on the belief that human disease is best treated with truly human therapeutics. Their discovery platform, developed by Wyatt and his five former 10X Genomics colleagues, has already been tapped by Merck in a partnering deal potentially worth $800million plus. The first two of their immune system-derived antibodies are heading toward the clinic in Atopic Dermatitis, and the Series A round to fund those trials attracted interest from Regeneron's venture arm.
On a more personal note, this episode also offers great insight into Wyatt's own journey into biotech and the entrepreneurial traits that lead to him going 'all-in' on Infinimmune. He also gives his advice for anyone in a similar position looking to go on that journey.
-
Episode 223 - Brent Richards -Founder & CEO | 5 Prime Sciences
10 september 2026 · 16 min
In this episode of The BioHub Podcast, Amber is joined by Dr. Brent Richards, Founder and CEO of 5 Prime Sciences, a company helping biotech, pharma and investors use human genetics to make better drug development decisions. Lees meer
Brent shares his background in clinical medicine and human genetics, the story behind 5 Prime Sciences, and how genetic evidence can help identify and validate drug targets. We explore the challenges of translating complex data into actionable insights, why understanding causal biology matters, and the opportunity to bring greater confidence to early drug discovery.
-
Episode 222 - Frederic Sweeney - CEO VedaBio
10 september 2026 · 36 min
Today I’m joined by Frédéric Sweeney, President and CEO of VedaBio. Lees meer
Fred has spent his career at the intersection of healthcare, diagnostics, venture capital and company building. He’s also been involved with a number of companies as an investor, board member and advisor.
Today, Fred is leading VedaBio, which is developing a new approach to molecular diagnostics using CRISPR. The company’s technology is designed to deliver highly accurate molecular detection much faster and closer to the point of care, with the goal of making sophisticated molecular testing much more accessible.
I’m really looking forward to hearing about Fred’s journey through the industry, what he’s learned from working across startups, large diagnostics companies and venture capital, and then diving into what VedaBio is building and where he sees the future of molecular diagnostics going.
-
Episode 221 - Steve Tregay - Managing General Partner Mission Biocapital
8 september 2026 · 28 min
In this episode of The BioHub by Avetix, I’m joined by Steve Tregay, Managing General Partner at Mission BioCapital. Lees meer
Steve shares his journey across research, pharma, biotech company building and venture capital, including the story behind founding FORMA Therapeutics and the lessons that experience taught him about creating successful biotech companies.
We also discuss how Mission BioCapital approaches early-stage company creation, what Steve looks for in founders and new opportunities, the role big pharma plays in the biotech ecosystem, and what he believes separates the companies that ultimately succeed from those that don’t.
-
Episode 220 - Hans Schambye - CEO BOOST Pharma
3 september 2026 · 25 min
In this episode of The BioHub by Avetix, I’m joined by Hans Schambye, CEO of BOOST Pharma. Lees meer
Hans shares what drew him to BOOST and the opportunity to develop what could become the first disease-modifying treatment for osteogenesis imperfecta. We discuss the challenge of taking a novel cell therapy from early clinical success towards Phase III, and what it takes to build the company around that journey.
We also explore the lessons Hans has learned from leading and scaling multiple biotech companies, how the CEO role changes through different stages of growth, and where he sees the cell and gene therapy landscape heading next.
-
Episode 219 - Prakash Raman - CEO of InduPro Therapeutics
2 september 2026 · 36 min
We were delighted to be joined by Prakash Raman, Ph.D., CEO of InduPro Therapeutics. Lees meer
Prakash brings more than two decades of experience across the biopharmaceutical industry, spanning business development, licensing, portfolio strategy, venture creation and executive leadership. Before joining InduPro, he was President and CEO of Ribon Therapeutics, following a period as Senior Partner and Chief Business Development Officer at Flagship Pioneering. Prior to that, he spent almost 14 years at Novartis, ultimately becoming Global Head of Business Development and Licensing for NIBR, where he was involved in a number of significant partnerships and acquisitions.
Today at InduPro, Prakash is helping build a company around a differentiated proximity biology platform, using an understanding of how proteins interact and are spatially organised to develop new therapeutics across oncology and immunology. The company has recently announced a $77 million Series B, entered into collaborations with companies including Lilly, Sanofi and Lonza, and has moved its lead programme, IDP-001, into the clinic.
So today, we’re going to talk about Prakash’s journey through biotech, what he learned from operating inside big pharma and venture, how he thinks about building companies and platforms, the opportunity around proximity biology, and what it takes to translate a differentiated scientific idea into a successful biotech business.
-
Episode 218 - JD Finley & Mitch Jones - Palisade Bio
31 augustus 2026 · 24 min
On this episode we're joined by Palisade Bio's CEO & CMO, JD Finley & Mitch Jones. Lees meer
In Q2 2026, Palisade released promising ph1 data for their lead asset - PALI2108 - a PDE4 inhibitor. With recent IND clearance for their ph2 ASCENTRA-UC study, we discuss that data, and what real success looks like clinically & commercially for the business & asset moving forward, in an increasingly busy IBD market.
We hope you enjoy the episode.
-
Episode 217 - Kristen Wong - Partner Altitude VC
27 augustus 2026 · 27 min
In this episode of The BioHub by Avetix, I’m joined by Kristen Wong of Altitude Life Science Ventures. Lees meer
Kristen shares her journey into venture capital and how she thinks about identifying the people and companies worth backing at the earliest stages. We discuss why the investments you pass on can be just as valuable as the ones you make, the importance of founder emotional intelligence, and what the SVB crisis taught her about supporting companies through uncertainty.
We also explore where AI is genuinely changing biotech and investing, why Kristen writes about the industry, and the lessons she has learned from working closely with founders and company builders.
-
Episode 216 - Tom Ciulla - CEO Ikarovec
17 augustus 2026 · 20 min
In this episode we meet Tom Ciulla, CEO of Ikarovec, one of the most exciting gene therapy biotechs in The UK and the ophthalmology scene more broadly. Lees meer
Ikarovec isn't Tom's first rodeo - playing a role in the rise of Iveric, Spark, Viridian, and Nanoscope - but as a first-time CEO, tune in to hear what excited him the most about Ikarovec's bicistronic platform, their plans for clinical trials in GA & RP, and the latest on their Series A.
-
Episode 215 - Nykode - Michael & Agnete - CEO & CSO
13 augustus 2026 · 37 min
In this episode of The BioHub by Avetix, I’m joined by Michael Engsig, CEO of Nykode Therapeutics, and Agnete Fredriksen, Co-Founder and Chief Scientific Officer. Lees meer
Michael and Agnete share the story behind Nykode, how the company’s technology has evolved, and what they’ve learned from building a biotech around a novel approach to immunotherapy.
We also discuss the balance between scientific ambition and commercial execution, the challenges of developing new cancer treatments, how the CEO and CSO roles work together, and where they see the future of cancer immunotherapy heading.
-
Episode 214 - David Crean - CBO at MediciNova
10 augustus 2026 · 33 min
In this episode of The BioHub Podcast by Avetix, Ben sits down with Dr. David Crean, Chief Business Officer at MediciNova, to explore a career spanning biotechnology, investment, M&A and strategic partnering. Lees meer
The conversation explores David’s journey into biotech, how he evaluates opportunities and partnerships, and the decisions that shape the development of emerging therapeutics. We also discuss MediciNova’s work in neurological disease, including the development of MN-166 (ibudilast), and the challenges of advancing therapies in areas such as ALS and other complex CNS disorders.
David also shares his perspective on business development in today’s biotech market, what makes an asset attractive to potential partners, how smaller companies can position themselves effectively, and how the relationship between science, financing and deal-making has evolved throughout his career.
-
Episode 215 - Kathleen Gallagher - CEO at Atrium Therapeutics
10 augustus 2026 · 38 min
We were delighted to be joined by Kathleen Gallagher, CEO of Atrium Therapeutics. Lees meer
Kathleen has built a fascinating career across the biotech industry, with experience spanning corporate communications, investor relations, clinical development and executive leadership. Before founding Atrium, she spent time at companies including Merrimack Pharmaceuticals and Akcea Therapeutics, before joining Avidity Biosciences, where she ultimately became Chief Program Officer.
At Avidity, Kathleen was closely involved in the company’s evolution and the development of its RNA therapeutics platform, including its work in myotonic dystrophy. The company’s journey ultimately culminated in its landmark acquisition by Novartis for up to $12 billion, one of the largest transactions in the biotech sector.
Following that experience, Kathleen took on the CEO of Atrium Therapeutics. Atrium is developing targeted RNA therapies for genetically driven cardiovascular diseases, with the ambition of addressing serious rare diseases where patients currently have limited treatment options.
Today, we’re going to talk about Kathleen’s journey through biotech, how her career evolved from communications and investor relations into drug development and ultimately the CEO role, what she learned from helping build Avidity, and what it was like to go through such a significant company transaction.
We’ll also explore the opportunity in RNA therapeutics, the decision to start Atrium, what it takes to build a biotech from the ground up, and Kathleen’s perspective on leadership, culture and what makes an early-stage biotech successful.
-
Episode 213 - Fred Aslan - CEO Artiva Bio
7 augustus 2026 · 29 min
In this episode of The BioHub by Avetix, I’m joined by Fred Aslan, President and CEO of Artiva Biotherapeutics. Lees meer
Fred shares his journey across venture capital, business development and biotech leadership, including his time at Venrock and Vividion, and how those experiences shaped the way he now leads Artiva.
We discuss what it takes to build and scale a biotech, how investor experience changes the way you make decisions as a CEO, the opportunity for off-the-shelf cell therapies, and where Fred sees the future of the cell therapy space heading.
-
Episode 212 - Luis Pena - Founder & CEO Evommune
6 augustus 2026 · 21 min
In this episode of The BioHub by Avetix, I’m joined by Luis Peña, Co-Founder, President and CEO of Evommune. Lees meer
Luis shares his journey from scientist to biotech founder, including the story behind building Dermira and the lessons he took from its acquisition by Eli Lilly. We discuss why he decided to start again with Evommune and the company’s ambition to develop new treatments for chronic inflammatory diseases.
We also explore what it takes to build and finance a biotech, the transition into the CEO role, how Luis approaches leadership, and what he believes separates companies that successfully turn strong science into meaningful medicines.
-
Episode 211 - Meredith Kaya - Corsera Health
4 augustus 2026 · 17 min
In Q1 of this year, I sat down with Meredith, CFO at Corsera Health, to discuss the future of cardiovascular health and why prediction and prevention are becoming increasingly important in improving outcomes long before a CVD diagnosis.We explored what it takes to build a company at the intersection of science, data and healthcare, how finance and strategy support innovation.A really insightful conversation with Meredith on the opportunities and challenges of building a company focused on tackling one of the world's leading causes of death. Lees meer
-
Episode 210 - Dana Watt - Partner at Breakout Ventures
4 augustus 2026 · 24 min
In this episode of the BioHub by Avetix, we’re joined by Dana Watt, Partner at Breakout Ventures, to explore how she evaluates ambitious science-led businesses at the earliest stages. Lees meer
Dana discusses her journey from neuroscience and company building into venture capital, what separates an exciting technology from an investable company, and the signals she looks for in scientific founders. We also explore how Breakout supports companies beyond capital, the changing investment environment for biotech and deep tech, and where Dana sees the greatest opportunities emerging across biology and technology.
A brilliant conversation for scientists, founders and anyone interested in how transformative ideas make the leap from the lab into the market.
Dana is currently a Partner at Breakout Ventures and has a background spanning cellular and molecular neuroscience, company formation and early-stage life-science investment.
-
Episode 209 - Pam Stetkiewicz Lyora Therapeutics
3 augustus 2026 · 23 min
Todays episode we welcomed Pam Stetkiewicz from Lyora Therapeutics on the BioHub Podcast.
-
Episode 208 - Handol Kim - CEO Variational AI
3 augustus 2026 · 25 min
In this episode of The BioHub by Avetix, I’m joined by Handol Kim, Co-Founder and CEO of Variational AI. Lees meer
Recorded at BIO 2026, Handol shares his unconventional journey from more than two decades in technology into biotech, and why he chose to apply generative AI to one of science’s most difficult challenges: discovering new medicines. Variational AI’s Enki platform is purpose-built to generate novel, synthesizable small molecules designed around a specific target product profile.
We discuss the realities behind the AI hype, where the technology can genuinely improve drug discovery, the challenge of building credibility at the intersection of technology and biology, and the lessons Handol has learned from building companies throughout his career.
-
Episode 207 - Ola Wlodek - CEO of Constructive Bio
30 juli 2026 · 31 min
We were delighted to be joined by Ola Włodek, a biotech executive and the CEO of Constructive Bio, a company at the forefront of synthetic biology and the development of new ways to engineer biology and create novel molecules. Lees meer
Ola brings a wealth of experience across the life sciences industry, with a background spanning strategy, operations, and business leadership. At Constructive Bio, she is part of the team working to translate cutting-edge synthetic biology into a platform capable of creating entirely new possibilities for drug discovery and development.
In today’s conversation, we’ll explore Ola’s career journey, and the potential of the company’s technology to fundamentally change how we think about designing and developing new medicines. We’ll also discuss the challenges of scaling a highly innovative biotech, the next major inflection points for the business, and Ola’s perspective on where the industry is heading.